OTCMKTS:BMXMF - BioMerieux Stock Price, News & Analysis

0.00 (0.00 %)
(As of 08/20/2019 04:00 PM ET)
Today's Range
Now: $81.30
50-Day Range
MA: $82.17
52-Week Range
Now: $81.30
Average VolumeN/A
Market Capitalization$9.62 billion
P/E RatioN/A
Dividend YieldN/A
bioMérieux SA provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that involves culturing biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as measures the specific biomarkers of various pathologies, such as metabolic, hormonal, infectious, etc. Read More…

Industry, Sector and Symbol

Industry Private households



Sales & Book Value

Annual Sales$2.58 billion
Book Value$16.58 per share



Market Cap$9.62 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive BMXMF News and Ratings via Email

Sign-up to receive the latest news and ratings for BMXMF and its competitors with MarketBeat's FREE daily newsletter.

BioMerieux (OTCMKTS:BMXMF) Frequently Asked Questions

What is BioMerieux's stock symbol?

BioMerieux trades on the OTCMKTS under the ticker symbol "BMXMF."

Has BioMerieux been receiving favorable news coverage?

News articles about BMXMF stock have trended positive on Tuesday, according to InfoTrie. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioMerieux earned a daily sentiment score of 2.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the near term. View News Stories for BioMerieux.

Who are some of BioMerieux's key competitors?

What other stocks do shareholders of BioMerieux own?

Who are BioMerieux's key executives?

BioMerieux's management team includes the folowing people:
  • Mr. Alexandre Mérieux, Chairman & CEO (Age 45)
  • Mr. Guillaume Bouhours, Exec. VP and Exec. VP of Fin., Purchasing & Information Systems (Age 43)
  • Sylvain Morgeau, Investor Relations
  • Ms. Valérie Leyldé, Exec. VP of HR and Communications
  • Mr. Michel Baguenault, Exec. VP & Company Sec.

How do I buy shares of BioMerieux?

Shares of BMXMF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioMerieux's stock price today?

One share of BMXMF stock can currently be purchased for approximately $81.30.

How big of a company is BioMerieux?

BioMerieux has a market capitalization of $9.62 billion and generates $2.58 billion in revenue each year. BioMerieux employs 10,800 workers across the globe.View Additional Information About BioMerieux.

What is BioMerieux's official website?

The official website for BioMerieux is http://www.biomerieux.com/.

How can I contact BioMerieux?

BioMerieux's mailing address is 376 CHEMIN DE L`ORME, MARCY L`ETOILE I0, 69280. The company can be reached via phone at 33-4-78-87-20-00 or via email at [email protected]

MarketBeat Community Rating for BioMerieux (OTCMKTS BMXMF)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  79 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  152
MarketBeat's community ratings are surveys of what our community members think about BioMerieux and other stocks. Vote "Outperform" if you believe BMXMF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMXMF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel